What exactly changed in the LFST analyst rating on Feb 25, 2026?

BMO Capital maintained an **Outperform** rating on LFST and raised its price target to **$10** from **$8** on February 25, 2026, as reported by TheFly.

How should investors interpret the LFST analyst rating from BMO?

A maintained Outperform with a higher PT indicates BMO expects improved performance. Investors should verify with upcoming earnings, cash flow, and utilization data before changing allocations.

Does the LFST analyst rating change guarantee stock upside?

No. The LFST analyst rating update signals analyst optimism but does not guarantee gains. Use the PT alongside company fundamentals and risk factors when making decisions.

Where can I read the original note on this LFST analyst rating?

The BMO note raising LifeStance to a **$10** target is summarized on TheFly and listed in market calendars like Benzinga for earnings context. [source](https://thefly.com/permalinks/entry.php/id4301007/6702286394/LFST-LifeStance-price-target-raised-by--at-BMO-Capital)

Analyst Ratings

BMO Maintains Outperform on LFST LifeStance Health Group Feb 2026, PT $10

ByHuzaifa Zahoor February 26, 2026

LFST analyst rating: On February 25, 2026 BMO Capital maintained an Outperform on LifeStance Health Group, Inc. (LFST) and raised its price target to $10 from $8. The move, logged by TheFly the same day, signals continued analyst confidence despite a near-term stock dip of -0.92% ($-0.07). This LFST analyst rating keeps BMO’s constructive stance intact and gives investors a fresh reference point for upside vs. the current market valuation.